IP Library Granted Patent US 8,962,620
Granted Patent B2
US 8,962,620 · App. 14/070,675 · Granted Feb 24, 2015

Substituted 6,5-fused bicyclic heteroaryl compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,620
App. No.
14/070,675
Granted
Feb 24, 2015
Kind
B2
Abstract

The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Claims (16)

1. A method of treating lymphoma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (IIIa) or a pharmaceutically acceptable salt thereof:

wherein

each of R 1 , R 3 , R 8 , and R 11 is H;

each of R 2 and R 4 is methyl;

R 6 is phenyl or pyridinyl, each substituted with one -Q 2 -T 2 , in which Q 2 is a methyl linker and T 2 is morpholinyl, and R 6 is optionally further substituted with methyl or Cl; and

R 7 is cyclopentyl or isopropyl.

2. The method of claim 1 , wherein R 6 is phenyl substituted with one -Q 1 -T 1 .

3. The method of claim 2 , wherein R 7 is cyclopentyl.

4. The method of claim 1 wherein the lymphoma is selected from the group consisting of B-cell lymphoma, diffuse large B-cell lymphoma, germinal center B cell-like lymphoma, cutaneous T-cell lymphoma, AIDS-related lymphoma, nervous system lymphoma, follicular lymphoma, and non-Hodgkin lymphoma.

5. The method of claim 1 wherein the lymphoma is B-cell lymphoma.

6. The method of claim 1 , wherein R 6 is pyridinyl substituted with one -Q 2 -T 2 .

7. The method of claim 6 , wherein R 7 is cyclopentyl.

8. The method of claim 1 , wherein the compound is selected from

and pharmaceutically acceptable salts thereof.

9. The method of claim 1 , wherein the compound is

10. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2013
From: KUNTZ, KEVIN WAYNE; OLHAVA, EDWARD JAMES; CHESWORTH, RICHARD; DUNCAN, KENNETH WILLIAM
To: EPIZYME, INC.
Reel/Frame 031752/0047 →